The treatment of perianal skin horseshoe melanoma by advancement flap (Y-V shaped) and the assessment of outcome over a long-term follow-up
AbstractA horseshoe perianal skin melanoma was treated by cutaneous advancement flap (Y-V shaped) and the outcome was investigated over a long-term follow-up. Objects of investigation were the history taking, the preoperative work-up, the adopted surgical procedure, and the histological and immune-histochemical findings concerning additional lesions found during the follow-up. The follow-up lasted 140 months. In this patient, a previous breast cancer was diagnosed and treated. Local diffusion of soft tissue, nodes, and anal sphincter infiltration or distant metastasis were not shown preoperatively. A wide excision with an advancement flap Y-V was carried out. Histological findings showed a leve l II of Clark with Breslow 0.65 mm. No local or distant recurrences were found by follow-up. Sixty months later, two pigmented lesions (0.3 0.2 mm) were detected and removed. Histologically, a hyperpigmentation of the basal layer of epidermis and immunostaining with Melan-A and CD 117 confirmed th e absence of any significant melanocytic proliferation. Ninety months after the first procedure, a new small cell carcinoma of the right lung was detected leading the patient to death after 140 months. The findings of this report raise issues related to plastic and reconstructive modality but also to oncological outcome. We were also able to recognize a possible compromised immune deficiency over a considerable life span. However, the occurrence of melanoma did not affect...
CONCLUSION: Regarding limited evidence patients with oligometastatic disease origin from non-gastrointestinal tumors could benefit from liver resection. Tumor biology and response to targeted individualized systemic therapy become more important in this scenario. PMID: 29767820 [PubMed - as supplied by publisher]
Authors: Xu L, Cheng L, Yang F, Pei B, Liu X, Zhou J, Zhu Y, Wang S Abstract Breast cancer is the second leading cause of cancer‑associated mortality, and metastatic breast cancer is responsible for 90% of patient mortalities. Given that JWA represses the proliferation, invasion and metastasis of a number of other human tumor cells, including melanoma, esophageal, hepatocellular and gastric carcinomas, via mitogen‑activated protein kinase or integrin signaling, the present study investigated the expression and function of JWA in human breast cancers. The results showed that the expression level of JWA was signi...
Authors: Wang Y, Lan GB, Peng FH, Xie XB Abstract Renal transplantation is associated with an increased risk of cancers at multiple sites; however, the relationships between increased cancer risk and participant characteristics remain unclear. We searched PubMed, Embase, and the Cochrane Library to identify prospective observational studies performed up to July 2017. Totally 11 prospective studies reported data on 79,988 renal transplant recipients were included. Renal transplant recipients were found to display a higher risk of all cancers (standard incidence ratio [SIR]: 2.89; 95% CI: 2.13-3.91; P
Brain metastases (BM) are the most common intracranial neoplastic disease in adults, with an incidence of 9 –17% among all brain tumors (Nayak et al., 2012). They are usually caused by lung cancer (either non-small cell (NSCLC) and small cell (SCLC) histologies), breast cancer, melanoma and renal cell carcinoma, with a raising incidence related to the improvements in diagnostic and treatment approaches (Berghoff et al., 2014). However, prognosis remains poor, with a median overall survival (OS) ranging from 3 to 27 months (Brastianos et al., 2013), rendering BM still an unmet medical need.
Brain metastases (BM) are the most common intracranial neoplastic disease in adults, with an incidence of 9-17% among all brain tumors (Nayak et al., 2012). They are usually caused by lung cancer (either non-small cell (NSCLC) and small cell (SCLC) histologies), breast cancer, melanoma and renal cell carcinoma, with a raising incidence related to the improvements in diagnostic and treatment approaches (Berghoff et al., 2014). However, prognosis remains poor, with a median overall survival (OS) ranging from 3 to 27 months (Brastianos et al., 2013), rendering BM still an unmet medical need.
Publication date: Available online 19 March 2018 Source:Respiratory Medicine Case Reports Author(s): Konstantinos Sapalidis, Nikos Schizas, Achileas Lazopoulos, Parthena Kamparoudi, Dimitris Paliouras, Chrysa Sardeli, Fotis Konstantinou, Fotis Chatzinikolaou, Pavlos Sarafis, Paul Zarogoulidis, Ioanna Kougioumtzi, Nikolaos Katsikogiannis, Ilias Karapantzos, Chrysa Karapantzou, Stella Laskou, Charilaos Koulouris, Stylianos Mantalobas, Dimitris Giannakidis, Isaak Kesisoglou, Nikos Barbetakis Multiple primary malignant neoplasms (MPMN) is an uncommon phenomenon, while the diagnosis of such conditions is very significant. Cons...
ConclusionsBecause second primary malignancy developed often after achieving CR by dCRT for ESCC, it should be followed carefully.
CONCLUSIONS: Because second primary malignancy developed often after achieving CR by dCRT for ESCC, it should be followed carefully. PMID: 29520523 [PubMed - as supplied by publisher]
Photochem. Photobiol. Sci., 2018, Accepted Manuscript DOI: 10.1039/C7PP00358G, PaperMarius S. Eng, Jagdip Kaur, Lina Prasmickaite, Anette Weyergang, Birgit O. Engesaeter, Ellen Skarpen, Kristian Berg, Michael G. Rosenblum, Gunhild Mari Maelandsmo, Anders Hogset, Soldano Ferrone, Pal Kristian Selbo Triple-negative breast cancer (TNBC) and malignant melanoma are highly aggressive cancers that widely express the cell surface chondroitin sulfate proteoglycan 4 (CSPG4/NG2). CSPG4 plays an important role in tumor cell... The content of this RSS Feed (c) The Royal Society of Chemistry
CONCLUSION: The response rates and overall survival of patients with NSCLC, renal carcinoma and triple negative breast cancer of good performance status receiving anti-PD-1 therapy outside of a clinical trial are consistent with clinical trial data. However, patients with poor ECOG performance status are unlikely to respond. Careful patient selection and counseling about the potential outcomes of self-funding treatment in this setting is needed. PMID: 29498208 [PubMed - as supplied by publisher]